HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dalrymple-Hay, M.J.R. Articles by McCaughan, B.C. Search for Related Content PubMed PubMed Citation Articles by Dalrymple-Hay, M.J.R. Articles by McCaughan, B.C. Related Collections Lung - cancer

Eur J Cardiothorac Surg 2002;21:611-615
© 2002 Elsevier Science NL

Pulmonary metastatic melanoma — the survival benefit associated with positron emission tomography scanning

Royal Prince Alfred Hospital, Sydney, NSW, Australia

Received 10 October 2000; received in revised form 6 December 2001; accepted 3 January 2002.

* Corresponding author. Department of Cardio-thoracic Surgery, Plymouth Hospital, Plymouth PL6 8DH, UK. Tel.: +44-1752-763-833
e-mail: malcolm.dalrymple-hay{at}virgin.net

Objective: Positron emission tomography (PET) scanning is more sensitive at detecting metastatic disease than conventional radiological techniques. For patients with pulmonary metastatic melanoma, we investigate if PET scanning to detect occult extra pulmonary disease prior to thoracotomy and metastectomy is associated with improved survival compared to patients staged by conventional radiology. Methods: Between November 1984 and December 1999, 121 patients (90 males, 31 females) have undergone a thoracotomy and pulmonary metastectomy for metastatic melanoma. The age range was 19–84 years (mean 57, median 59). In every case all palpable nodules were removed and the diagnosis confirmed histologically. A total of 68 (56%) patients had a PET scan preoperatively, 53 (44%) underwent conventional or nuclear imaging. Patients with only radiologically isolated pulmonary disease are included. Results: Survival is 100% complete and totals 238 pt/years (mean 2.2 years, median 1.4 years). Survival (±SE) at 1, 3, 5 and 7 years for all patients is 68% (±4.5) (n=67), 36.6% (±5.2) (n=27), 22.1% (±4.8) (n=15) and 13.5% (±4.2) (n=7), respectively. Survival (±SE) was significantly better at 3 and 5 years in patients who underwent a PET scan preoperatively (Log rank P=0.002). There was no significant difference in survival by 7 years. Conclusions: There is a significant survival benefit associated with excluding extra pulmonary disease using a PET scan prior to thoracotomy and metastectomy. We recommend that PET scanning be used in the investigation of patients with pulmonary metastatic melanoma prior to metastectomy.

Key Words: Pulmonary metastatic melanoma • Positron emission tomography scanning • Metastectomy

This article has been cited by other articles:

				D. Fuster, S. Chiang, G. Johnson, L. M. Schuchter, H. Zhuang, and A. Alavi Is 18F-FDG PET More Accurate Than Standard Diagnostic Procedures in the Detection of Suspected Recurrent Melanoma? J. Nucl. Med., August 1, 2004; 45(8): 1323 - 1327. [Abstract] [Full Text] [PDF]